Linda M Robison

Summary

Affiliation: Washington State University
Country: USA

Publications

  1. ncbi Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants
    Linda M Robison
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, Washington 99164 6510, USA
    CNS Drugs 16:129-37. 2002
  2. ncbi Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99
    Linda M Robison
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Int Clin Psychopharmacol 19:17-22. 2004
  3. ncbi Datapoints: trends in ADHD and stimulant use among adults: 1995-2002
    Linda M Robison
    Department of Health Policy and Administration, Washington State University, P.O. Box 646510, Pullman, Washington 99164-6510, USA
    Psychiatr Serv 56:1497. 2005
  4. ncbi Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA 99210 1495, USA
    Headache 52:198-203. 2012
  5. ncbi Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:139-44. 2012
  6. ncbi Ethnicity/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia
    Megan N Willson
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USA
    Am J Cardiovasc Drugs 10:105-8. 2010
  7. ncbi Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, 99210 1495, USA
    Clin Drug Investig 32:e17-24. 2012
  8. ncbi α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:353-60. 2012
  9. ncbi Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychia
    Tracy L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, Washington 99164 6510, USA
    Clin Ther 31:1478-87. 2009
  10. ncbi Rate of obesity in U.S. ambulatory patients with diabetes mellitus: a national assessment of office-based physician visits
    Joshua J Neumiller
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA 99217, United States
    Prim Care Diabetes 3:197-9. 2009

Detail Information

Publications15

  1. ncbi Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants
    Linda M Robison
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, Washington 99164 6510, USA
    CNS Drugs 16:129-37. 2002
    ....
  2. ncbi Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99
    Linda M Robison
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Int Clin Psychopharmacol 19:17-22. 2004
    ..5% of those aged 5-8 years. The reasons for the gender and age group differences discerned in this study require further investigation, as does the reason why 15.1% of children were receiving no treatment beyond the office-based visit...
  3. ncbi Datapoints: trends in ADHD and stimulant use among adults: 1995-2002
    Linda M Robison
    Department of Health Policy and Administration, Washington State University, P.O. Box 646510, Pullman, Washington 99164-6510, USA
    Psychiatr Serv 56:1497. 2005
  4. ncbi Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA 99210 1495, USA
    Headache 52:198-203. 2012
    ....
  5. ncbi Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:139-44. 2012
    ....
  6. ncbi Ethnicity/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia
    Megan N Willson
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USA
    Am J Cardiovasc Drugs 10:105-8. 2010
    ..Nevertheless, previous research suggests that there remain racial/ethnic disparities in the access to and quality of care for hyperlipidemia...
  7. ncbi Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, 99210 1495, USA
    Clin Drug Investig 32:e17-24. 2012
    ..Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD)...
  8. ncbi α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:353-60. 2012
    ..It has been shown that weekly or monthly infusion of human α-AT is effective in raising serum α-AT levels to desired levels (>80 mg/dL), with few, if any, adverse effects...
  9. ncbi Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychia
    Tracy L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, Washington 99164 6510, USA
    Clin Ther 31:1478-87. 2009
    ..Tricyclic antidepressants (TCAs) were not recommended because of insufficient efficacy evidence, as well as adverse events...
  10. ncbi Rate of obesity in U.S. ambulatory patients with diabetes mellitus: a national assessment of office-based physician visits
    Joshua J Neumiller
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA 99217, United States
    Prim Care Diabetes 3:197-9. 2009
    ..S. National Ambulatory Medical Care Survey (NAMCS). Our findings indicate a significant proportion of U.S. ambulatory patients with DM present with obesity and greater clinical acuity than patients with DM alone...
  11. ncbi Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?
    Tracy L Skaer
    College of Pharmacy, Washington State University, PO Box 646510, Pullman, WA 99164 6510, USA
    Diabetes Educ 32:940-53. 2006
    ....
  12. ncbi Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, WA 99164 6510, USA
    Int Clin Psychopharmacol 23:106-9. 2008
    ..6 to 5.2 for blacks, and from 3.0 to 5.6 for Hispanics. It can be concluded that by 2003-2004, diagnostic and treatment rates were comparable among blacks and Hispanic, but were less than half the observed rates for whites...
  13. ncbi Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Department of Health Policy and Administration, Washington State University, P O Box 646510, Pullman, WA 99164 6510, USA
    Gen Hosp Psychiatry 30:73-6. 2008
    ..private) of U.S. patients aged 5-18 years who were hospitalized with a primary diagnosis of depression and (b) to discern the mean hospital length of stay and mean charge per day by payer type...
  14. ncbi Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, WA 99164 6510, USA
    Headache 48:126-9. 2008
    ..To discern the prevalence of concomitant use of a triptan and a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake inhibitor (SNRI) in the USA...
  15. ncbi Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission
    David A Sclar
    Department of Health Policy and Administration, Washington State University, Pullman, WA 99164 6510, USA
    Drugs R D 6:149-56. 2005
    ....